Agenus stock doubles as $340M placement backs colon drug
Agenus secured an oversubscribed $340 million private placement to fund a late-stage colon cancer trial, sending its shares up 100% and extending its cash runway into 2031.
Agenus shares surged roughly 100% on Monday after the biotech firm locked in an oversubscribed private placement worth up to $340 million. The capital injection will fund a pivotal Phase 3 trial for its botensilimab and balstilimab combination therapy targeting a highly resistant form of colon cancer.
The transaction yields roughly $85 million in immediate gross proceeds, with another $255 million contingent on the full exercise of attached warrants. Commodore Capital led the round, drawing backing from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. Assuming the warrants are fully exercised, the company estimates the funding will sustain operations through the end of 2031.
The financing targets a significant commercial gap in oncology. High-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer represents a more than $7 billion annual market in the US alone. There have been no new curative-intent therapies approved for this patient population in over two decades.
Investors are betting on mid-stage data from the NEST and UNICORN studies, which tested the drug combination as a neoadjuvant treatment. Agenus reported pathologic responses in 60% to 70% of patients, with pathologic complete responses reaching about 30%. Crucially for an oncology investment, all treated patients remained disease-free across median follow-up periods of nine to 18 months.
The upcoming ROBBIN trial will enroll 850 patients globally to compare the immunotherapy combination plus standard of care against standard of care alone. The primary metric is event-free survival. Agenus noted it has already aligned the trial's core design elements—covering the patient cohort, dosing regimen, and interim analysis plan—with the US Food and Drug Administration.
Clinical milestones are structured over a multi-year horizon. The first patient is expected to be dosed in the first quarter of 2027, with initial pathologic response data due in the second half of that year. Final event-free survival data is slated for the second half of 2030. "Our plan to prioritize neoadjuvant BOT+BAL in MSS colon cancer reflects both the strength of the emerging clinical evidence and the opportunity to bring this important combination regimen to patients where it may have the greatest impact," said Chief Executive Officer Garo H. Armen.
